FibroGen Inc
NASDAQ:FGEN

Watchlist Manager
FibroGen Inc Logo
FibroGen Inc
NASDAQ:FGEN
Watchlist
Price: 8.56 USD -0.47%
Market Cap: 34.7m USD

Net Margin
FibroGen Inc

2 598.9%
Current
23%
Average
-6.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2 598.9%
=
Net Income
215.7m
/
Revenue
8.3m

Net Margin Across Competitors

No Stocks Found

FibroGen Inc
Glance View

Market Cap
34.6m USD
Industry
Biotechnology

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 566 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in discovering, developing and commercializing a pipeline of therapeutics. The company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). The company is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The company also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. The firm is also enrolling patients in its two Phase III trials of pamrevlumab patients.

FGEN Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2 598.9%
=
Net Income
215.7m
/
Revenue
8.3m
What is the Net Margin of FibroGen Inc?

Based on FibroGen Inc's most recent financial statements, the company has Net Margin of 2 598.9%.

Back to Top